Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5083945 · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| KRAS WT A | EXPERIMENTAL | - |
| KRAS WT B | ACTIVE_COMPARATOR | - |
| KRAS mutant A | EXPERIMENTAL | - |
| KRAS mutant B | ACTIVE_COMPARATOR | - |
| A non-squamous | EXPERIMENTAL | - |
| A squamous | EXPERIMENTAL | - |
| B non-squamous | ACTIVE_COMPARATOR | - |
| B squamous | ACTIVE_COMPARATOR | - |
| A | EXPERIMENTAL | - |
| B | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| FOLFIRI | DRUG | standard iv chemotherapy |
| RO5083945 | DRUG | 1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter |
| cetuximab | DRUG | 400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week |
| cisplatin | DRUG | standard treatment, up to 6 cycles |
| gemcitabine | DRUG | standard treatment, up to 6 cycles |
| pemetrexed | DRUG | standard treatment, up to 6 cycles |
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Carcinoma of the colon and/or rectum * Disease progression during or within 6 months of last dose of oxaliplatin containing first-line combination therapy for metastatic disease * ECOG performance status 0-1 * Adequate hematological, rena...
Top 20 of 77 competitors
RO5083945 is an investigational oncology drug being studied for the treatment of neoplasms, non-squamous non-small cell lung cancer, head and neck cancer, and colorectal cancer. It is developed by Roche Holding AG (RHHBY) and is currently in Phase 2 clinical development.
RO5083945 is a small molecule that targets the epidermal growth factor receptor (EGFR), as indicated by its clinical trials in patients with EGFR+ solid tumors. By targeting EGFR, it aims to interfere with cancer cell growth and survival pathways.
RO5083945 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various oncology indications.
RO5083945 is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials, with no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities.
RO5083945 has been studied in several completed trials, including NCT00721266 (Phase 1, solid tumors), NCT01046266 (Phase 1, head and neck cancer), NCT01185847 (Phase 2, non-small cell lung cancer), and NCT01326000 (Phase 2, colorectal cancer). These trials enrolled a total of 169 patients.
No, RO5083945 is not the same as cetuximab. In a Phase 2 trial for metastatic colorectal cancer, RO5083945 was compared against FOLFIRI plus cetuximab or FOLFIRI alone, indicating they are distinct treatments being evaluated in the same setting.